Free Newsletter
NIAID backs Emergent work; Antigenics reports a loss;
Vaccine Research
The NIAID has provided $4.5 million in research grants to Emergent BioSolutions for its work on vaccines for botulism and anthrax. Report
Scientists hope a vaccine is on the horizon for tularemia, a fatal disease caused by the pathogen Francisella tularensis, an organism of concern as a potential biological warfare agent. Release
Avantogen has been moving to acquire a majority of Hawaii Biotech, attracted by approaching Phase I trials for new West Nile disease and dengue fever vaccines. Report
Medical Marketing International has raised £1 million to fund research on a cancer vaccine and other work. Story
Vaccine market
Antigenics, which is marketing the cancer vaccine Oncophage in Russia, reported a net loss of $12.2 million in the last quarter. Release
Scotland has launched a campaign to raise awareness of the new vaccine for cervical cancer. Story
Physicians in Florida are reporting a spike in the number of whooping cough cases. Story
UK officials say they have had to destroy almost half a million doses of vaccine which had expired. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
